Skip to main content
SpringerLink
Log in

Issues in the design and analysis of AIDS clinical trials

  • Chapter
Recent Advances in Clinical Trial Design and Analysis

Part of the book series: Cancer Treatment and Research ((CTAR,volume 75))

Abstract

The AIDS epidemic has provoked a massive response from the worldwide scientific community. To address the need for rapid evaluation of new treatments for the primary viral infection and related opportunistic infections, malignancies, and other illnesses, the Federal Government established the largest publicly-sponsored program of clinical trials ever undertaken. As intended, these resources made it possible to enlist many gifted academic and government scientists in the effort, including biostatisticians and other clinical trialists. There have been advances in connection with several aspects of clinical trial design and analysis, and the body of this chapter highlights a few of these. Before beginning, however, we consider the question of why it is necessary, or at least useful, to focus on advances in methodology for AIDS clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fauci AS (1993). The National Institutes of Health Five-Year Plan for HIV-Related Research. Office of AIDS Research: Washington, DC.

    Google Scholar 

  2. Byar DP, Schoenfeld DA, Green SB, et al. (1990). Design considerations for AIDS trials. N Engl J Med 323:1343–1348.

    Article  PubMed  CAS  Google Scholar 

  3. Green SB, Ellenberg SS, Finkelstein DM, et al. (1990). Issues in the design of drug trials for AIDS. Controlled Clin Trials 11:80–87.

    Article  PubMed  CAS  Google Scholar 

  4. Ellenberg SS, Cooper E, Eigo J, et al. (1992). Studying treatments for AIDS: new challenges for clinical trials. Controlled Clin Trials 13:272–292.

    Article  PubMed  CAS  Google Scholar 

  5. Ellenberg SS, Finkelstein DM, Schoenfeld DA (1992). Statistical issues arising in AIDS clinical trials (with comments and rejoinder). J Am Stat Assoc 87:562–583.

    Article  Google Scholar 

  6. Dixon DO, Rida WN, Fast PE, Hoth DF (1993). HIV vaccine trials: Some design issues including sample size calculation. J AIDS 6:485–496.

    CAS  Google Scholar 

  7. Ellenberg SS, Dixon DO (1994). Statistical issues in designing clinical trials of AIDS treatments and vaccines. J Stat Planning Inf 42:123–135.

    Article  Google Scholar 

  8. Amato DA, Lagakos SW (1990). Considerations in the selection of end points for AIDS clinical trials. J AIDS 3 (Suppl 2):S64–S68.

    Google Scholar 

  9. Lagakos SW, Hoth DF (1992). Surrogate markers in AIDS: Where are we? Where are we going? Ann Intern Med 116:599–601.

    PubMed  CAS  Google Scholar 

  10. Moss A (1990). Laboratory markers as potential surrogates for clinical outcomes in AIDS trials. J AIDS 3 (Suppl 2):S69–S71.

    Google Scholar 

  11. Mildvan D (1993). Clinical validation of virologic and immunologic assays. Presentation at the 17th AIDS Clinical Trials Group Meeting.

    Google Scholar 

  12. Machado SG, Gail MH, Ellenberg SS (1990). On the use of laboratory markers as surrogates for clinical endpoints in the evaluation of treatment for HIV infection. J AIDS 3:1065–1073.

    CAS  Google Scholar 

  13. Prentice RL (1989). Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431–440.

    Article  PubMed  CAS  Google Scholar 

  14. Choi S, Lagakos SW, Schooley RT, Volberding PA (1993). CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 118:674–680.

    PubMed  CAS  Google Scholar 

  15. Lin DY, Fischl MA, Schoenfeld DA (1993). Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 12:835–842.

    Article  PubMed  CAS  Google Scholar 

  16. DeGruttola V, Wulfsohn M, Fischl MA, Tsiatis A (1993). Modeling the relationship between survival and CD4-lymphocytes in patients with AIDS and AIDS-related complex. JAIDS 6:359–365.

    Google Scholar 

  17. Concorde Coordinating Committee (1994). Concorde: MRC/ANRS randomised, double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343:871–881.

    Article  Google Scholar 

  18. Kosorok MR, Fleming TR (1993). Using surrogate failure time data to increase cost effectiveness in clinical trials. Biometrika 80:823–833.

    Article  Google Scholar 

  19. Fleming T, Prentice R, Pepe M, Glidden D (1994). Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 13:955–968.

    Article  PubMed  CAS  Google Scholar 

  20. Pepe MS (1992). Inference using surrogate outcome data and a validation sample. Biometrika 79:344–365.

    Article  Google Scholar 

  21. Pepe MS, Reilly M, Fleming TR (in press). Auxiliary outcome data and the mean score method. J Stat Planning Inference.

    Google Scholar 

  22. Finkelstein DM, Schoenfeld DA (1994). Analyzing survival in the presence of an auxiliary variable. Stat Med 13:1747–1754.

    Article  PubMed  CAS  Google Scholar 

  23. Guyatt G, Feeny D, Patrick D (1991). Issues in quality-of-life measurement in clinical trials. Controlled Clin Trials 12 (Suppl):81S–90S.

    Article  PubMed  CAS  Google Scholar 

  24. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D (1992). Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 305:1074–1077.

    Article  CAS  Google Scholar 

  25. Cox DR, Fitzpatrick R, Gore SM, Spiegelhalter DJ, Fletcher AE, Jones DR (1992). Quality-of-life assessment: can we keep it simple (with discussion)? J R Stat Soc A 155: 353–393.

    Article  Google Scholar 

  26. Williams JBW, Rabkin JG (1991). The concurrent validity of items in the quality of life index in a cohort of HIV-positive and HIV-negative gay men. Controlled Clin Trials 12 (Suppl):129S–141S.

    Article  PubMed  CAS  Google Scholar 

  27. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR (1981). Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis 34:585–597.

    Article  PubMed  CAS  Google Scholar 

  28. Wu AW, Rubin HR, Mathews WC, Ware JE, Brysk LT, Hardy WD, Bozzette SA, Spector SA, Richman DD (1991). A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Med Care 29:786–798.

    Article  PubMed  CAS  Google Scholar 

  29. Glasziou PP, Simes RJ, Gelber RD (1990). Quality adjusted survival analysis. Stat Med 9:1259–1276.

    Article  PubMed  CAS  Google Scholar 

  30. Gelber RD, Gelman RS, Goldhirsch A (1989). A quality of life oriented end point for comparing therapies. Biometrics 45:781–796.

    Article  PubMed  CAS  Google Scholar 

  31. Fischl MA, Richman DD, Hansen N, et al. (1990). The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 112:727–737.

    PubMed  CAS  Google Scholar 

  32. Gelber RD, Lenderking WR, Cotton DJ, et al. (1992). Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 116:961–966.

    PubMed  CAS  Google Scholar 

  33. Volberding PA, Lagakos SW, Koch MA, et al. (1990). Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 322:941–949.

    Article  PubMed  CAS  Google Scholar 

  34. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA (1994). Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330:738–743.

    Article  PubMed  CAS  Google Scholar 

  35. Sackett DL, Snow JC (1979). The magnitude of compliance and noncompliance. In Compliance in Health Care, RB Haynes, DW Taylor, DL Sackett (eds.). Baltimore, MD, The Johns Hopkins University Press, 11-22.

    Google Scholar 

  36. Schork MA, Remington RD (1967). The determination of sample size in treatment-control comparisons for chronic disease studies in which dropout or non-adherence is a problem. J Chron Dis 20:233–239.

    Article  PubMed  CAS  Google Scholar 

  37. Lachin JM, Foulkes MA (1986). Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507–519.

    Article  PubMed  CAS  Google Scholar 

  38. Peduzzi P, Wittes J, Detre K, Holford T (1993). Analysis as-randomized and the problem of non-adherence: an example for the Veterans Affairs randomized trial of coronary artery bypass surgery. Stat Med 12:1185–1195.

    Article  PubMed  CAS  Google Scholar 

  39. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB (1991). Analysis of clinical trials by treatment actually received: is it really an option? Stat Med 10:1595–1506.

    Article  PubMed  CAS  Google Scholar 

  40. May GS, DeMets DL, Friedman LM, et al. (1981). The randomized clinical trial: bias in analysis. Circulation 64:669–673.

    Article  PubMed  CAS  Google Scholar 

  41. Coronary Drug Research Group (1980). Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 302:1038–1041.

    Google Scholar 

  42. Efron B, Feldman D (1991). Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 86:9–26.

    Article  Google Scholar 

  43. Mark SD, Robins JM (1993). A method for the analysis of randomized trials with compliance information: an application to the multiple risk factor intervention trial. Controlled Clin Trials 14:79–97.

    Article  PubMed  CAS  Google Scholar 

  44. Albert JM, DeMets DL (1994). On a model-based approach to estimating efficacy in clinical trials. Stat Med 13:2323–2335.

    Article  PubMed  CAS  Google Scholar 

  45. Robins JM, Tsiatis AA (1991). Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 20:2609–2631.

    Article  Google Scholar 

  46. Lagakos SW, Lim LL-Y, Robins JM (1990). Adjusting for early treatment termination in comparative clinical trials. Stat Med 9:1417–1424.

    Article  PubMed  CAS  Google Scholar 

  47. Spilker B (1991). Guide to Clinical Trials. New York: Raven Press.

    Google Scholar 

  48. Lim LL-Y (1992). Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 48:619–630.

    Article  PubMed  CAS  Google Scholar 

  49. Richardson D, Liou S-H, Kahn JO (1993). Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J AIDS 6:1212–1223.

    CAS  Google Scholar 

  50. Pritzker L, Ogus J, Hansen MH (1965). Computer editing methods -some applications and results. Proceedings 35th session, Belgrade. Bull Int Stat Inst 41:442–465.

    Google Scholar 

  51. Naus JI (1977). Data Quality Control and Editing. New York: Marcel Dekker.

    Google Scholar 

  52. Altmann L (1994). Report of fraud in a major breast cancer study. New York Times.

    Google Scholar 

  53. Deming WE (1986). Out of the Crisis. Cambridge, MA: Massachusetts Institute of Technology, Center for Advanced Engineering Study.

    Google Scholar 

  54. West M, Winkler R (1991). Data base error trapping and prediction. A focus on Bayesian methods. J Am Stat Assoc 86:987–996.

    Article  Google Scholar 

  55. Matthews JNS, Altman DG, Campbell MJ, Royston P (1990). Analysis of serial measurements in medical research. Br Med J 300:230–235.

    Article  CAS  Google Scholar 

  56. Frison L, Pocock S (1992). Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 11:1685–1704.

    Article  PubMed  CAS  Google Scholar 

  57. Foulkes MA, Ellenberg SS (in preparation). Large simple trials of HIV therapies. In AIDS Clinical Trials, DM Finkelstein, DA Schoenfeld (eds).

    Google Scholar 

  58. Yusuf S, Collins R, Peto R (1984). Why do we need some large, simple trials? Stat Med 3:409–420.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Dennis O. Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey M. Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Biomathematics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 237, Houston, Texas, 77030, USA

    Peter F. Thall Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dixon, D.O., Albert, J.M. (1995). Issues in the design and analysis of AIDS clinical trials. In: Thall, P.F. (eds) Recent Advances in Clinical Trial Design and Analysis. Cancer Treatment and Research, vol 75. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2009-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2009-2_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5830-5

  • Online ISBN: 978-1-4615-2009-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation